The identification of recurrent gene fusions in common epithelial cancers—for example, TMPRSS2/ERG in prostate cancer [3] and EML4/ALK in nonsmall cell lung carcinomas [4],[5]—has raised the question of whether fusion genes are pathogenetically important also in ovarian carcinomas. This evidence concerns the gene EML4 and ovarian carcinoma.